Treatment-emergent all-causality grade 3 adverse events more common ( P < .001 ) with temsirolimus/bevacizumab were mucosal inflammation , stomatitis , hypophosphatemia , hyperglycemia , and hypercholesterolemia , whereas neutropenia was more common with IFN/bevacizumab .